We hope to study components within the blood that may predict success, failure or other
associated complications in relation to the type of vascular access being used.
Renal failure affects more than 350,000 patients in the United States. All patients
undergoing dialysis must have access to the vascular system (blood stream) for hemodialysis
treatment. Methods of access include a catheter, or tube, that goes through the skin and
into a large vein, a surgically created connection of a vein to an artery called an AV
fistula, or a surgically created connection of a vein to artery using a graft or plastic
tube. Previous research has shown considerable differences in the function and success in
these types of vascular access for dialysis. Research investigators try to explain these
differences and find the causes and explanations for the variations seen in vascular access.
Forty patients undergoing dialysis treatment will be evaluated by analyzing serum specimens
obtained during outpatient hemodialysis access. Serum will also be collected from ten
pre-dialysis patients and ten normal volunteers for comparison. Pre-dialysis patients are
those who have Stage 3, 4, or 5 chronic kidney disease but are not yet on dialysis and have
never had any type of created vascular access. Normal subjects will have no kidney disease,
autoimmune disorders, recent (<6 months) chemotherapy treatment or corticosteroid use, or
other chronic condition determined by the investigator to interfere with cytokine and
inflammatory markers. The serum specimens will be analyzed for cytokine/inflammatory
markers and correlated with clinical access type and other medical data and demographic
- Male and female patients of Dr. William Jennings and Dr. Pranay Kathuria
undergoing dialysis therapy as outpatients
- Male and female patients of Dr. Pranay Kathuria who have been diagnosed with Stage 3,
4, or 5 chronic kidney disease, but who are not yet on dialysis.
- Healthy volunteers with no kidney disease, autoimmune disorders, recent (<6 months)
chemotherapy treatment or corticosteroid use, or other chronic condition determined
by the investigator to interfere with cytokine and inflammatory markers.
- 18 to 90 years of age
- under 18 years of age
- over 90 years of age
- institutionalized patients
- pregnant individuals
- patients with mental illness who are not able to give informed consent